Technology

The vice president of technology strategy & strategic partnerships at Syneos Health discusses how new digital technologies are changing the ways that data is collected, shared, analyzed.

AI allows patients, doctors, and payers to make informed decisions based on evidence at a much faster pace.

In an interview with Pharm Exec Associate Editor Don Tracy, Alessandro Zannini, Global After-Sales Manager, Stevanato Group discusses the benefits of generative artificial intelligence.

Rahman discusses the new opportunities that digital twins present to researchers.

The Health Cube will increase remote and virtual care options for populations living in remote areas.

Butta discusses how new technologies are being implemented in at-home devices.

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

The meeting is scheduled for May in Switzerland.

Webinar Date/Time: Thursday, May 23, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Webinar Date/Time: Thursday, May 9, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Webinar Date/Time: Thursday, April 18, 2024 at 10am EDT | 7am PDT | 3pm BST | 4pm CEST

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.

Although life science organizations are not immune to the benefits of artificial intelligence, it’s important to integrate it with caution because there is no “one-size fits all” approach.

Anderson discusses how AI can be used to take data collected by different processes and bring it into a usable format.

Webinar Date/Time: Thursday, March 21, 2024 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET

A Harvard Business School Healthcare Alumni Association (HBSHAA) Q&A with Professor Deborah Ancona, founder of the MIT Leadership Center.

While no company has yet achieved the full promise of AI to radically accelerate time to market, meaningful strides are being made across the drug discovery funnel.

Investigators harness machine learning to evaluate response to sertraline treatment for major depressive disorder.

Its path and application could model the same road as AI.

In this video interview with Pharm Exec Associate Editor Miranda Schmalfuhs, Dr. Jo Varshney, CEO & Founder of VeriSIMLife, discusses how artificial intelligence and machine learning can assist in the drug shortage problem.

The use of artificial intelligence (AI) in drug development has been hampered by issues that have caused a gap between AI’s potential and its full utilization in this space.

EVERSANA's chief innovation discusses his experience with Apple's new device and how he thinks it might impact the life sciences industry.

By capitalizing on AI advancements, pushing the boundaries of personalized medicine with theranostics, and strengthening digital healthcare networks, radiopharmaceuticals are poised to transform healthcare from a reactive to a proactive discipline.

Portals are finally a viable channel as life sciences companies shift to modular to build their digital ecosystems, create and approve content, and deliver omnichannel experiences.

Dr. Russo discusses how modern innovations will shape the way hospitals operate in years to come.